
|Articles|June 1, 2001
Studies confirm low-dose oral contraceptive treats acne effectively
Washington - The results of Phase III clinical trials demonstrate the safety and efficacy of a low-dose oral contraceptive containing ethinyl estradiol 20 mcg and levonorgestrel 100 mcg (Alesse) for the treatment of moderate acne, reported Diane M. Thiboutot, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
2
Targeting MRGPRX2: Early Human Data for a Novel CSU Approach
3
What Counts as “Short-Term” Systemic Corticosteroids in Atopic Dermatitis, and Why It Matters
4
Phase 3 Results Signal a New Era for Oral Targeted Therapy in Psoriasis
5










